These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15931814)

  • 21. Nasopharyngeal brushing: a convenient and feasible sampling method for nucleic acid-based nasopharyngeal carcinoma research.
    Zhang PF; Zheng XH; Li XZ; Tian T; Zhang SD; Hu YZ; Jia WH
    Cancer Commun (Lond); 2018 Apr; 38(1):8. PubMed ID: 29764493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
    Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
    Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Quantitative and localized detection of Epstein-Barr virus infectious status in nasopharyngeal carcinoma tissue].
    Jiang WH; Zhao SP; Yin ZH; Li F; Chen ZH; Xiao JY
    Ai Zheng; 2005 Jul; 24(7):796-800. PubMed ID: 16004803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region.
    Pramanik R; Arora S; Sharma P; Biswas A; Nayak B; Thakar A; Sharma A; Ghose S
    J Med Virol; 2022 Feb; 94(2):720-728. PubMed ID: 34750844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-free Epstein-Barr virus-DNA in patients with nasopharyngeal carcinoma: Plasma versus urine.
    Sengar M; Chorghe S; Jadhav K; Singh S; Laskar SG; Pai P; Aggarwal JP; D'Cruz A; Chaturvedi P; Deshpande M; Chaukar D; Budrukkar A; Gupta T; Murthy V; Kane S; Thakur M; Rangarajan V; Kannan S; Shet T; Kode J
    Head Neck; 2016 Apr; 38 Suppl 1():E1666-73. PubMed ID: 26667883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.
    Stoker SD; Wildeman MA; Novalic Z; Fles R; van der Noort V; de Bree R; Braunius WW; van den Broek GB; Kreike B; Kross KW; Juwana H; Ramayanti O; Verkuijlen SA; de Boer JP; Greijer AE; Middeldorp JM; Tan IB
    Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1557-67. PubMed ID: 25929413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
    Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma.
    Hsiao JR; Jin YT; Tsai ST
    Cancer; 2002 Feb; 94(3):723-9. PubMed ID: 11857305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA.
    Wang WY; Lin TY; Twu CW; Tsou HH; Lin PJ; Liu YC; Huang JW; Hsieh HY; Lin JC
    Oncotarget; 2016 Jul; 7(27):42608-42616. PubMed ID: 27191654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma.
    Tan EL; Selvaratnam G; Kananathan R; Sam CK
    BMC Cancer; 2006 Sep; 6():227. PubMed ID: 16995954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of plasma Epstein-Barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma.
    Tan EL; Looi LM; Sam CK
    Singapore Med J; 2006 Sep; 47(9):803-7. PubMed ID: 16924363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of two laboratory extraction techniques for the detection of Epstein-Barr virus in the saliva of nasopharyngeal carcinoma patients.
    Shan J; Pow EH; Tsang PC; Perera RA; Kwong DL
    J Investig Clin Dent; 2014 May; 5(2):104-8. PubMed ID: 24574317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor heterogeneity measured on F-18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein-Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma.
    Chan SC; Chang KP; Fang YD; Tsang NM; Ng SH; Hsu CL; Liao CT; Yen TC
    Laryngoscope; 2017 Jan; 127(1):E22-E28. PubMed ID: 27435352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
    Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
    Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of Epstein-Barr virus in nasopharynx tissue and desquamatine cell for diagnosis of nasopharyngeal carcinoma].
    Sun Z; Xiao C; Jiang W; Feng X; Liu Y
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Feb; 20(4):153-4. PubMed ID: 16711437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
    Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
    Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.